1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015

Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Irritable Bowel Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Irritable Bowel Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015
Introduction 6
Irritable Bowel Syndrome 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Irritable Bowel Syndrome 25
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Irritable Bowel Syndrome Therapeutics Clinical Trials 32
Prominent Drugs 33
Latest Clinical Trials News on Irritable Bowel Syndrome 34
Dec 18, 2014: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation 34
Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan 34
Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation 35
Oct 21, 2014: Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation 35
Oct 21, 2014: Salix's TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea 36
Oct 17, 2014: Salix Pharmaceuticals Outlines Data of Rifaximin Presents at American College of Gastroenterology 2014 Annual Scientific Meeting 38
Clinical Trial Profiles 39
Clinical Trial Overview of Top Companies 39
GlaxoSmithKline plc 39
Clinical Trial Overview of GlaxoSmithKline plc 39
Novartis AG 43
Clinical Trial Overview of Novartis AG 43
Actavis plc 45
Clinical Trial Overview of Actavis plc 45
Astellas Pharma Inc. 46
Clinical Trial Overview of Astellas Pharma Inc. 46
Salix Pharmaceuticals Ltd. 47
Clinical Trial Overview of Salix Pharmaceuticals Ltd. 47
Ironwood Pharmaceuticals, Inc. 48
Clinical Trial Overview of Ironwood Pharmaceuticals, Inc. 48
AstraZeneca PLC 49
Clinical Trial Overview of AstraZeneca PLC 49
Ono Pharmaceutical Co., Ltd. 50
Clinical Trial Overview of Ono Pharmaceutical Co., Ltd. 50
Almirall, S.A. 51
Clinical Trial Overview of Almirall, S.A. 51
A. Menarini Industrie Farmaceutiche Riunite Srl 52
Clinical Trial Overview of A. Menarini Industrie Farmaceutiche Riunite Srl 52
Clinical Trial Overview of Top Institutes / Government 53
Mayo Clinic 53
Clinical Trial Overview of Mayo Clinic 53
University of North Carolina 54
Clinical Trial Overview of University of North Carolina 54
University of Nottingham 55
Clinical Trial Overview of University of Nottingham 55
Maastricht University Medical Center 56
Clinical Trial Overview of Maastricht University Medical Center 56
Sahlgrenska University Hospital 57
Clinical Trial Overview of Sahlgrenska University Hospital 57
Chinese University of Hong Kong 58
Clinical Trial Overview of Chinese University of Hong Kong 58
Cedars-Sinai Medical Center 59
Clinical Trial Overview of Cedars-Sinai Medical Center 59
Karolinska Institute 60
Clinical Trial Overview of Karolinska Institute 60
University of California, Los Angeles 61
Clinical Trial Overview of University of California, Los Angeles 61
Baylor College of Medicine 62
Clinical Trial Overview of Baylor College of Medicine 62
Five Key Clinical Profiles 63
Appendix 155
Abbreviations 155
Definitions 155
Research Methodology 156
Secondary Research 156
About GlobalData 157
Contact Us 157
Disclaimer 157
Source 157

List of Tables

Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region, 2015* 7
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 13
Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 15
Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 18
Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Irritable Bowel Syndrome Therapeutics, Global, Suspended Clinical Trials, 2015* 25
Irritable Bowel Syndrome Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26
Irritable Bowel Syndrome Therapeutics, Global, Terminated Clinical Trials, 2015* 27
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 30
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2015* 39
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 43
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2015* 45
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2015* 46
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Salix Pharmaceuticals Ltd., 2015* 47
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Ironwood Pharmaceuticals, Inc., 2015* 48
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2015* 49
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Ono Pharmaceutical Co., Ltd., 2015* 50
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Almirall, S.A., 2015* 51
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by A. Menarini Industrie Farmaceutiche Riunite Srl, 2015* 52
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2015* 53
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by University of North Carolina, 2015* 54
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Nottingham, 2015* 55
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Maastricht University Medical Center, 2015* 56
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Sahlgrenska University Hospital, 2015* 57
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Chinese University of Hong Kong, 2015* 58
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Cedars-Sinai Medical Center, 2015* 59
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Karolinska Institute, 2015* 60
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2015* 61
Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2015* 62

List of Figures

Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 13
Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 15
Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 18
Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 30
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
GlobalData Methodology 156

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.